Abstract 468P
Background
Traditional Chinese Medicine (TCM) is effective in alleviating side-effects of radiotherapy and chemotherapy. While TCM is popular among cancer patients, their health-seeking behavior is not well described. Safety data regarding concurrent use with oncology treatment is lacking.
Methods
This is a retrospective cohort study from a tertiary oncology institute. All patients who had follow-up visits in both the TCM clinic and Oncology department of the Queen Elizabeth Hospital in Hong Kong from 2011 to 2022 were recruited.
Results
Fourteen patients were identified. Twelve (85.7%) were female, median age was 64. Nine (64.3%) of them were early-stage (I-II) cancers. Amongst these 14 patients, the distribution of cancer types was as follows: breast cancer (n=6), cervical cancer (n=3), head and neck cancer (n=2), ovarian cancer (n=2) and gastrointestinal cancer (n=1). Eight (57.4%) patients started to receive TCM advice at the same year of diagnosis, while half of them received conventional cancer treatment (chemotherapy, n=2; targeted therapy, n=1; hormone therapy, n=1) simultaneously. No CTCAE v5 Grade 3 or above adverse events were observed among patients having the concomitant use of TCM and chemotherapy. However, none of them informed the oncologist regarding the use of TCM. Patients tends to complain more symptoms to TCM practitioner than to Oncologists. The major reasons for TCM treatments were the treatment-emergent side effects (n=9), followed by the wish for reconditioning after anti-cancer treatment (n=6). Patients reported that the use of herbal medicine (H) improved insomnia (3 out of 4 pts), dizziness (n=1) and cancer pain (n=1). Moreover, the combined use of H and acupuncture showed clinical improvement in chemotherapy-induced numbness (1 out of 2 pts), pain associated with avascular necrosis (n=1), fatigue (n=1) and alopecia (n=1).
Conclusions
TCM demonstrated promising results in improving long-term treatment morbidity. Yet, most patients were not willing to disclose the use of TCM. Strengthening the communication between oncologists and patients would reduce the potential risk of herb-drug interactions.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract